Skip to main content
Top
Published in: Osteoporosis International 3/2011

01-03-2011 | Review

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009

Authors: S. Lee, P. Glendenning, C. A. Inderjeeth

Published in: Osteoporosis International | Issue 3/2011

Login to get access

Abstract

The purposes of the study were to review available published literature on magnitude of non-adherence with osteoporosis regimens and to determine the association between frequency and modality of medication administration with patient preference and adherence. We searched peer-reviewed journal databases—MEDLINE, EMBASE, Biosis and Derwent Drug File for publications (January 1979 to January 2009) including MeSH terms—“patient preference”, “adherence” and “compliance” based on “dosing frequency” and “modality”. Since adherence was difficult to accurately quantify, preference, compliance and persistence were evaluated. Patients’ preference and adherence at 12 months were higher with weekly over daily bisphosphonates (≥84% preference for weekly, medication possession ratios (MPR) 60–76% vs 46–64%; persistence 43.6–69.7% vs 31.7–55.7%). MPR reported for oral bisphosphonates were 68–71% at 12 months. At 2 years, only 43% of patients had MPR ≥80% for daily and weekly bisphosphonates. Observational studies (6–12 months) reported discontinuation rates of 18–22% for daily and 7% for weekly bisphosphonates. Data on monthly bisphosphonates are conflicting and confounded by cost differences, patient support programmes and definition of persistence. Studies suggest patient preference for annual zoledronic acid infusions over weekly bisphosphonates (66.4–78.8% vs 9.0–19.7%, respectively), but no data on compliance or persistence are available. Drug effectiveness, side effects and route of administration were more important than frequency. Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important. Adherence is complex and difficult to quantify and may not be exclusively influenced by frequency of medication administration.
Literature
1.
go back to reference Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed
4.
go back to reference Haynes RB, McDonald H, Garg AX, Montague P (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev CD000011 Haynes RB, McDonald H, Garg AX, Montague P (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev CD000011
5.
go back to reference Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135CrossRefPubMed Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135CrossRefPubMed
6.
go back to reference Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMed Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMed
7.
go back to reference Adami S, Felsenberg D, Christiansen C et al (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881–889CrossRefPubMed Adami S, Felsenberg D, Christiansen C et al (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881–889CrossRefPubMed
8.
go back to reference Delmas PD, Recker RR, Chesnut CH 3rd et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798CrossRefPubMed Delmas PD, Recker RR, Chesnut CH 3rd et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798CrossRefPubMed
9.
go back to reference Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661CrossRefPubMed Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661CrossRefPubMed
10.
go back to reference Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed
11.
go back to reference Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501CrossRefPubMed Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501CrossRefPubMed
12.
go back to reference Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMed Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMed
13.
go back to reference O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD005326 O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD005326
14.
go back to reference Inderjeeth CA, Foo AC, Lai MM, Glendenning P (2009) Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 44:744–751CrossRefPubMed Inderjeeth CA, Foo AC, Lai MM, Glendenning P (2009) Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 44:744–751CrossRefPubMed
15.
go back to reference Haynes RB (1979) Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, pp 49–62 Haynes RB (1979) Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, pp 49–62
16.
go back to reference Rand CS (1993) Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 72:68D–74DCrossRefPubMed Rand CS (1993) Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 72:68D–74DCrossRefPubMed
17.
go back to reference Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37–55CrossRefPubMed Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37–55CrossRefPubMed
18.
go back to reference Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed
19.
go back to reference Compston J (2003) Do we need to monitor anti-osteoporosis treatement anyway? In: 30th European Symposium on Calcified Tissues. Rome, Italy Compston J (2003) Do we need to monitor anti-osteoporosis treatement anyway? In: 30th European Symposium on Calcified Tissues. Rome, Italy
20.
go back to reference Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMed Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMed
21.
go back to reference Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed
22.
go back to reference Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443CrossRefPubMed Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443CrossRefPubMed
23.
go back to reference Ho AY, Kung AW (2005) Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 39:1428–1433CrossRefPubMed Ho AY, Kung AW (2005) Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 39:1428–1433CrossRefPubMed
24.
go back to reference Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 814 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Manag Care Pharm 4:488–492 Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 814 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Manag Care Pharm 4:488–492
25.
go back to reference Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968CrossRefPubMed Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968CrossRefPubMed
26.
go back to reference McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287CrossRefPubMed McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287CrossRefPubMed
27.
go back to reference Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed
28.
go back to reference Penning-van Beest FJ, Goettsch WG, Erkens JA (2004) Persistence with bisphosphonate therapy among post-menopausal osteoporotic women and the impact of dosing frequency. Value Health 7:724 Penning-van Beest FJ, Goettsch WG, Erkens JA (2004) Persistence with bisphosphonate therapy among post-menopausal osteoporotic women and the impact of dosing frequency. Value Health 7:724
29.
go back to reference Cowell W, Fulford-Smith A, Poultney S (2005) Adherence with bisphosphonate treatment for osteoporosis in UK patients. Bone 36(Suppl 2):S409–S410 Cowell W, Fulford-Smith A, Poultney S (2005) Adherence with bisphosphonate treatment for osteoporosis in UK patients. Bone 36(Suppl 2):S409–S410
30.
go back to reference Harris ST, Siris ES, Abbott TA, Barr CE, Rosen CJ (2005) Reduced osteoporotic fracture risk in patients adherence to bisphosphonate therapy. In: Program & Abstracts of The Endocrine Society’s 87th Annual Meeting; 2005 4–7 June, p 3–382 Harris ST, Siris ES, Abbott TA, Barr CE, Rosen CJ (2005) Reduced osteoporotic fracture risk in patients adherence to bisphosphonate therapy. In: Program & Abstracts of The Endocrine Society’s 87th Annual Meeting; 2005 4–7 June, p 3–382
31.
go back to reference Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415–423CrossRefPubMed Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415–423CrossRefPubMed
33.
go back to reference Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefPubMed Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefPubMed
34.
go back to reference Richter A, Anton SE, Koch P, Dennett SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25:2307–2335, discussion 6CrossRefPubMed Richter A, Anton SE, Koch P, Dennett SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25:2307–2335, discussion 6CrossRefPubMed
35.
go back to reference Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886CrossRefPubMed Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886CrossRefPubMed
36.
go back to reference Kendler D, Kung AW, Fuleihan Gel H et al (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243–251CrossRefPubMed Kendler D, Kung AW, Fuleihan Gel H et al (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243–251CrossRefPubMed
37.
go back to reference Baroutsou B, Babiolakis D, Stamatiadou AE et al (2004) Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. Ann Rheum Dis 63(Supple 1):455 Baroutsou B, Babiolakis D, Stamatiadou AE et al (2004) Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. Ann Rheum Dis 63(Supple 1):455
38.
go back to reference Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shalom S (2005) Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 17:143–149PubMed Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shalom S (2005) Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 17:143–149PubMed
39.
go back to reference Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460CrossRefPubMed Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460CrossRefPubMed
40.
go back to reference Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861CrossRefPubMed Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861CrossRefPubMed
41.
go back to reference Sunyecz J, Gallagher R, MacCosbe PE (2006) Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. Female Patient 31:21–28 Sunyecz J, Gallagher R, MacCosbe PE (2006) Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. Female Patient 31:21–28
42.
go back to reference Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522–528PubMed Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522–528PubMed
43.
go back to reference Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249–1256CrossRefPubMed Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249–1256CrossRefPubMed
44.
go back to reference Silverman SL, Gold DT (2008) Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10:118–122CrossRefPubMed Silverman SL, Gold DT (2008) Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10:118–122CrossRefPubMed
45.
go back to reference Weiss TW, McHorney CA (2007) Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect 10:211–223CrossRefPubMed Weiss TW, McHorney CA (2007) Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect 10:211–223CrossRefPubMed
46.
go back to reference Weiss TW, Gold DT, Silverman SL, McHorney CA (2006) An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 22:949–960CrossRefPubMed Weiss TW, Gold DT, Silverman SL, McHorney CA (2006) An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 22:949–960CrossRefPubMed
47.
go back to reference Duarte JW, Bolge SC, Sen SS (2007) An evaluation of patients’ preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin Ther 29:488–503CrossRefPubMed Duarte JW, Bolge SC, Sen SS (2007) An evaluation of patients’ preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin Ther 29:488–503CrossRefPubMed
48.
go back to reference Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383–2391CrossRefPubMed Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383–2391CrossRefPubMed
49.
go back to reference Simon JA, Beusterien K, Hebborn A, Kline LN (2005) Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: a study. Female Patient 30:31–36 Simon JA, Beusterien K, Hebborn A, Kline LN (2005) Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: a study. Female Patient 30:31–36
50.
go back to reference Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903CrossRefPubMed Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903CrossRefPubMed
51.
go back to reference Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310CrossRefPubMed Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310CrossRefPubMed
52.
go back to reference Weiss TW, Henderson SC, McHorney CA, Cramer JA (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 23:2193–2203CrossRefPubMed Weiss TW, Henderson SC, McHorney CA, Cramer JA (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 23:2193–2203CrossRefPubMed
53.
go back to reference Silverman S, Cramer J, Sunyecz J et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12-month results from two retrospective databases [abstract W366]. In: 29th Annual Meeting of the American Society for Bone and Mineral Research; 2007 Sept 16–20; Honolulu, HI Silverman S, Cramer J, Sunyecz J et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12-month results from two retrospective databases [abstract W366]. In: 29th Annual Meeting of the American Society for Bone and Mineral Research; 2007 Sept 16–20; Honolulu, HI
54.
go back to reference Cooper A, Drake J, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905CrossRefPubMed Cooper A, Drake J, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905CrossRefPubMed
56.
go back to reference Richards JB, Cherkas LF, Spector TD (2007) An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr Med Res Opin 23:293–299CrossRefPubMed Richards JB, Cherkas LF, Spector TD (2007) An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr Med Res Opin 23:293–299CrossRefPubMed
57.
go back to reference Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23:1815–1821CrossRefPubMed Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23:1815–1821CrossRefPubMed
58.
go back to reference McClung M, Recker R, Miller P et al (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122–128CrossRefPubMed McClung M, Recker R, Miller P et al (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122–128CrossRefPubMed
59.
go back to reference Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238–1243CrossRefPubMed Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238–1243CrossRefPubMed
60.
go back to reference Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55:729–735CrossRefPubMed Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55:729–735CrossRefPubMed
61.
go back to reference Kendler DL, Bessette L, Hill CD et al (2009) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837–846CrossRefPubMed Kendler DL, Bessette L, Hill CD et al (2009) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837–846CrossRefPubMed
62.
go back to reference Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501CrossRefPubMed Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501CrossRefPubMed
63.
go back to reference Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683CrossRefPubMed Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683CrossRefPubMed
64.
go back to reference Grant AM, Avenell A, Campbell MK et al (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–1628CrossRefPubMed Grant AM, Avenell A, Campbell MK et al (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–1628CrossRefPubMed
65.
go back to reference Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2–S6CrossRefPubMed Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2–S6CrossRefPubMed
66.
go back to reference Inderjeeth CA, Glennon D, Petta A (2006) Study of osteoporosis awareness, investigation and treatment of patients discharged from a tertiary public teaching hospital. Intern Med J 36:547–551CrossRefPubMed Inderjeeth CA, Glennon D, Petta A (2006) Study of osteoporosis awareness, investigation and treatment of patients discharged from a tertiary public teaching hospital. Intern Med J 36:547–551CrossRefPubMed
Metadata
Title
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
Authors
S. Lee
P. Glendenning
C. A. Inderjeeth
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1335-x

Other articles of this Issue 3/2011

Osteoporosis International 3/2011 Go to the issue